ETS1 Identified as Dual Driver of Metastasis and Immune Evasion in Squamous Cell Carcinoma
By
@ccmb.usc.edu
Soggy bottom. Skim the top, leave the rest on the tray.
Summary
This study identifies the transcription factor ETS1 as a master regulator of a hybrid epithelial-mesenchymal transition (hEMT) program in upper aerodigestive squamous cell carcinoma (UASCC). Through single-cell RNA sequencing, researchers found that ETS1 drives both tumor metastasis and immune evasion by activating pro-metastatic genes and creating an immune-cold tumor microenvironment via STAT1 and PD-L1 activation. High ETS1 expression correlates with poor survival and resistance to immune checkpoint blockade. Drug screening revealed that ETS1-high cancers are vulnerable to HSP90 inhibitors like alvespimycin, which suppress ETS1 by disrupting HIF1α-mediated transcriptional activation, offering a potential targeted treatment strategy.
Key quotes
· 5 pulledETS1 was identified as a master regulator of the hEMT program, directly activating pro-metastatic genes and promoting distant spread in vivo.
Unexpectedly, ETS1 also orchestrated an immune-cold tumor microenvironment by transcriptionally activating the STAT1 and CD274 (PD-L1) genes, suppressing T lymphocyte infiltration, and elevating immune checkpoint molecules.
Clinically, high ETS1 expression in tumors strongly correlated with poor survival and resistance to immune checkpoint blockade (ICB) across multiple cohorts.
Drug screening demonstrated that ETS1-high cancers were vulnerable to HSP90 inhibitors (e.g., alvespimycin), which suppress ETS1 by disrupting HIF1α-mediated transcriptional activation.
These findings provide a roadmap for targeting aggressive ITH subsets and overcoming immunotherapy resistance.
You might also wanna read
Google's Debug program seeks EPA approval to release 64 million modified mosquitoes in California and Florida
Google's Debug program plans to release up to 64 million genetically modified "good" mosquitoes in California and Florida over two years to
bit.ly·41m ago
Researchers develop phage-based preventive treatment for newborn meningitis caused by E. coli K1
Researchers from the Biozentrum, University of Basel, and ETH Zurich have developed a novel preventive treatment for newborn meningitis caus
biozentrum.unibas.ch·1h ago
Daily pill daraxonrasib doubles survival for metastatic pancreatic cancer patients with KRAS mutation
A new daily pill called daraxonrasib has been shown to double survival time for metastatic pancreatic cancer patients with a KRAS mutation.
bbc.co.uk·4h ago
Exploring the science behind quantum effects in healthcare: separating research from pseudoscience
The article explores the intersection of quantum physics and healthcare, distinguishing between pseudoscientific "quantum therapies" and leg
newscientist.com·5h ago
Experimental pill daraxonrasib nearly doubles survival time in advanced pancreatic cancer trial
A novel experimental pill called daraxonrasib has shown promise in extending survival for patients with advanced pancreatic cancer. The drug
chicagotribune.com·6h agoExperimental pill daraxonrasib nearly doubles survival time in advanced pancreatic cancer trial
A novel experimental pill called daraxonrasib has shown promise in extending survival for patients with advanced pancreatic cancer. The drug
chicagotribune.com·6h ago